Collaboration Catalyzes Breakthroughs

Ilumina goes beyond creating cutting-edge tools, we're a collaborative partner, connecting you with industry-leading R&D and a global network of scientific support.



Our Mission: Incept valuable partnerships with academic institutions, pharmaceutical companies and population genomics programs that enable discovery, development, and commercialization of precision medicine globally.

Your vision, amplified: How Illumina turns vision into impact

Global presence with local connectivity

Scale and Expertise Expertise and solutions spanning discovery through clinical translation

Field-leading experience in regulatory strategy and commercialization

Omics Toolkit Largest pipeline of integrated omic and informatics tools¹

Collaborative Legacy Demonstrated, transformative impact through collaboration¹

More than

7,500
employees and

22,000
systems across

~165
countries
providing in-region
expertise/support.

https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=15da9928-16c1-453a-b908-a4469a1fc91c

Ambitious scientific leaders across industries are shaping the next era of precision medicine. Illumina collaborations help them go further.

Two recent examples are positioned for significant advances in drug discovery and future health outcomes


Faster, more-complete drug discovery through the Alliance for Genomic Discovery (AGD)



The AGD is an ongoing collaboration between Illumina, Nashville Biosciences, and nine leading pharmaceutical companies. The alliance has already delivered the most comprehensive clinical genomic dataset of its kind at unprecedented pace.

Through a diverse cohort with rich clinical data and Al analysis, **AGD unlocks insights often missed in homogeneous datasets**. The initiative has already identified **multiple drug candidates**, including several targets cited in Nature².

- ² https://www.nature.com/articles/s41467-025-57753-2
- https://www.prnewswire.com/news-releases/alliance-for-genomic-discovery-com pletes-250-000-whole-genomes-to-accelerate-drug-discovery-302405464.html



Improving real-world outcomes in Singapore: Precision Health Research Singapore (PRECISE)



PRECISE is a multi-year initiative advancing precision medicine in Singapore through genomics and data integration. In partnership with Illumina, the program sequenced 100,000 Singaporean genomes, making it Southeast Asia's most comprehensive population study.

Together, they've built Al-powered analysis platforms and developed local expertise and infrastructure to address ethnic disparities in genetic health.⁴

- https://www.npm.sg/news-and-events/press-releases/precise-illuminapartnership-agreement/
- ⁵ https://pubmed.ncbi.nlm.nih.gov/36335097/
- https://www.npm.sg/empowering-seamless-access-personalisedpharmacogenomic-information-on-the-go/
- https://www.npm.sg/news-and-events/editorial-features/from-reactive-toproactive-tracing-the-hereditary-cancer-risk/
- https://www.nature.com/articles/s41588-022-01274-x#:~:text=To%20provide%20 better%20coverage%20of,.edu.sg/

Clinically-relevant variants were identified:

1.05%

of Singaporeans carry genetic variants associated with familial hypercholesterolemia (FH)⁵ 26.8%

of Singaporeans carry genetic variant linked to medication side effects⁶

1 in 150

Singaporeans have BRCA1 or BRCA2 mutations⁷

Millions

of previously unreported genomic variants were uncovered8

Let's co-create what's next in precision medicine—your next breakthrough starts with a conversation.

